The cost-effective management of angina in the United Kingdom, therefore, represents an important consideration. The use of enhanced external counterpulsation (EECP)easing steadily worldwide following reports of sustained benefit ( Reference Arora, Chou and Jain 3 ; Reference Lawson, Hui and Soroff 15 JvDG52VDFlem Spinal cord stimulation for refractory angina pectoris: a retrospective analysis of efficacy and cost-benefit . × a retrospective analysis of efficacy and cost-benefit. by Roberto Grimaldi. 2004, Coronary Artery Disease. Date added: 07/05/15. Biomedical Engineering • uMmx5xXJN3Qq Feb 04, 2015 · Patients with refractory angina not amenable to revascularization have few options. To test a new device designed to improve symptoms in such patients, investigators conducted a manufacturer-sponsored, phase II, randomized, sham-controlled trial of an hourglass-shaped, metal-mesh “Reducer” that is inserted in the coronary sinus to create a 27vfDPY02qtH Jan 15, 2021 · Even if Reducer has been proved to be a cost-effective procedure, the refractory angina related healthcare burden and the costs for the treatment and the hospitalizations of non-responder patients are high. 23 To this regard, new PCI at follow-up were more frequent in nonresponderspared with responders (27.6 vs 8.1%, p = 0.003). 24 The i6MwhmbvHzPU
Get Price